Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors

Antwerp, Belgium, July 9, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that it has appointed David Epstein as non-executive board member and Chairman of its Board of Directors. David is an industry veteran and most recently served as Seagen’s Chief Executive Officer and as a member of its Board of Directors. Under his leadership, Seagen significantly grew its portfolio of innovative cancer medicines and was acquired for more than $43 billion by Pfizer in December 2023. Prior to Seagen, he served as Novartis Pharmaceuticals’ Chief Executive Officer. David has more than 30 years of drug development, deal-making, commercialization and leadership experience on a global scale. Over the course of his career, he has led the development and commercialization of over 30 new molecular entities, including Glivec, Tasigna, Gilenya, Cosentyx, Entresto and Padcev. He was named by FierceBiotech as one of the “25 most influential people in biopharma”.